| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Ravi Misra reiterates Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target f...
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Sell and lowers the price target from $...
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and raises the price target ...
Integra Lifesciences (NASDAQ:IART) is looking for Q4 Adj EPS of $0.79-$0.84 vs $0.92 analyst estimate. sees sales of $420.000 m...
Integra Lifesciences (NASDAQ:IART) narrows FY2025 Adj EPS guidance from $2.19-$2.29 to $2.19-$2.24 vs $2.21 analyst estimate. L...
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of ...
Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price tar...